708 related articles for article (PubMed ID: 26262510)
1. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
2. Update on Paragangliomas and Pheochromocytomas.
Lam AK
Turk Patoloji Derg; 2015; 31 Suppl 1():105-12. PubMed ID: 26177321
[TBL] [Abstract][Full Text] [Related]
3. A Guide to Pheochromocytomas and Paragangliomas.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
[TBL] [Abstract][Full Text] [Related]
4. [Genetics of paragangliomas and pheochromocytomas].
Favier J; Gimenez-Roqueplo AP
Med Sci (Paris); 2012; 28(6-7):625-32. PubMed ID: 22805139
[TBL] [Abstract][Full Text] [Related]
5. Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.
Nakamura E; Kaelin WG
Endocr Pathol; 2006; 17(2):97-106. PubMed ID: 17159241
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.
Dannenberg H; Komminoth P; Dinjens WN; Speel EJ; de Krijger RR
Endocr Pathol; 2003; 14(4):329-50. PubMed ID: 14739490
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
8. Genetics of pheochromocytomas and paragangliomas.
Opocher G; Schiavi F
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163
[TBL] [Abstract][Full Text] [Related]
9. Familial pheochromocytomas and paragangliomas.
King KS; Pacak K
Mol Cell Endocrinol; 2014 Apr; 386(1-2):92-100. PubMed ID: 23933153
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas.
Vogel TW; Brouwers FM; Lubensky IA; Vortmeyer AO; Weil RJ; Walther MM; Oldfield EH; Linehan WM; Pacak K; Zhuang Z
J Clin Endocrinol Metab; 2005 Jun; 90(6):3747-51. PubMed ID: 15769989
[TBL] [Abstract][Full Text] [Related]
12. Hereditary pheochromocytoma and paraganglioma.
Mazzaglia PJ
J Surg Oncol; 2012 Oct; 106(5):580-5. PubMed ID: 22648936
[TBL] [Abstract][Full Text] [Related]
13. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
14. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
Welander J; Söderkvist P; Gimm O
Endocr Relat Cancer; 2011 Dec; 18(6):R253-76. PubMed ID: 22041710
[TBL] [Abstract][Full Text] [Related]
15. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
Juhlin CC
Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
[TBL] [Abstract][Full Text] [Related]
16. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma: the expanding genetic differential diagnosis.
Bryant J; Farmer J; Kessler LJ; Townsend RR; Nathanson KL
J Natl Cancer Inst; 2003 Aug; 95(16):1196-204. PubMed ID: 12928344
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
19. Adrenal cortical tumors, pheochromocytomas and paragangliomas.
Lloyd RV
Mod Pathol; 2011 Apr; 24 Suppl 2():S58-65. PubMed ID: 21455202
[TBL] [Abstract][Full Text] [Related]
20. DNA flow cytometry in pheochromocytoma and paraganglioma.
Jung WH; Yang WI; Park C; Choi IJ
Yonsei Med J; 1992 Sep; 33(3):249-57. PubMed ID: 1292249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]